Understanding how pancreatic cancer responds to KRAS inhibitors
Official title: Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
Funded at Dana-Farber Cancer Inst · NIH-11023066 · Data updated 2026-11-12
This study is looking at how certain gene changes in pancreatic cancer might affect how well new treatments work, with the hope of finding better, personalized therapies for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $561,772 |
| NIH project number | 5R01CA276268-03 |
| Project ID | NIH-11023066 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
✕Less likely to help
Patients with non-pancreatic cancers or those without KRAS mutations may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a low survival rate. It aims to explore how mutations in the KRAS gene and other tumor suppressor genes affect the cancer's response to new KRAS inhibitors. By using advanced models, including human organoids and mouse models, the research will investigate the genetic and environmental factors that influence treatment outcomes. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer profiles.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for pancreatic cancer patients, potentially increasing survival rates.
How similar studies have gone: Other research has shown promising results with KRAS inhibitors in similar contexts, indicating a potential for success in this area.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Aguirre, Andrew James — Dana-Farber Cancer Inst
- Study coordinator: Aguirre, Andrew James
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.